22 июн. 2022 г. · This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people ...

This article presents the recommendations and suggestions for future research of an American Academy of Neurology (AAN) practice guideline on the efficacy and ...

12 мар. 2024 г. · Released in 2018, guidelines from the AAN on the use of disease-modifying therapies in patients with multiple sclerosis provide updated guidance ...

For the current dissemination-inspace criteria, MS lesions must be seen in at least two of the following four locations: cortical/juxtacortical, periventricular ...

Clinicians should prescribe alemtuzumab, fingolimod, or natalizumab for people with MS with highly active MS (Level B). Starting: Recommendation 15. Rationale.

It is recommended to treat acute MS relapses with a 3–5-day course of IV Methylprednisolone (IV-MP) at a daily dose of 500–1000 mg. It is appropriate to ...

1 июл. 2022 г. · The guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people ...

12 нояб. 2024 г. · The MENACTRIMS guidelines are set under extensive research conducted by the society executive members and their task forces to provided the ideal diagnosis, ...

17 сент. 2024 г. · We identified 2 evidence-based guidelines that included recommendations around switching from a first-line to a second-line therapy in patients ...

This article summarizes the findings and conclusions of an American Academy of Neurology (AAN) practice guideline on the efficacy and safety of disease- ...